<DOC>
	<DOCNO>NCT00912054</DOCNO>
	<brief_summary>To demonstrate superiority DuoTrav APS XALACOM® Ocular Surface Health patient open angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>DuoTrav APS Versus XALACOM® Ocular Surface Health</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>1 . Patients ≥ 18 year age . 2 . Must clinical diagnosis openangle glaucoma ( without pseudoexfoliation pigment dispersion component ) , ocular hypertension least one eye . 3 . Must willing able discontinue use topical ocular medication study medication duration study . 4 . Must IOP control monotherapy use XALACOM least 1 continuous month prior Visit 1 . 5 . Women childbearing potential must meet specific condition Visit 1 : 1 . Any abnormality prevent reliable applanation tonometry study eye ( ) . 2 . Presence ocular pathology either eye see slit lamp fundus exam may preclude safe administration test article safe participation study . 3 . Dry eye KCS , currently , treat use punctal plug , punctal cautery , Restasis® , topical ocular corticosteroid . 4 . Patients undergone keratorefractive ocular laser procedure , corneal surgery surgery corneal surface , within 1 year prior Visit1 5 . Any ocular laser surgery either eye within 3 month 6 . Patients undergone intraocular extraocular surgery , either eye , within 6 month prior Visit 1 . 7 . History progressive retinal optic nerve disease . 8 . Severe central visual field loss either eye base upon clinical judgment investigator . 9 . Any history , current evidence , infectious inflammatory ocular condition 10 . Ocular trauma within 6 month prior Visit 1 either eye , determined patient history and/or examination . 11 . History evidence corneal transplant transplant variant procedures 12 . Patients suspect diagnosed Sjogren 's syndrome . 13 . History current bronchial asthma , severe chronic obstructive pulmonary disease 14 . History current severe , unstable uncontrolled cardiovascular , hepatic , renal disease . 15 . History spontaneous current hypoglycemia uncontrolled diabetes . 16 . History current severe allergic rhinitis bronchial hyper reactivity . 17 . Intolerance/hypersensitivity component medication 18 . Use systemic medication chronic basis stable dose regimen least 30 day prior Visit 1 , anticipate change dose regimen medication course study . 19 . Use ocular medication XALACOM® within 7 day 20 . Use corticosteroid within 30 day Visit 1 , anticipate use corticosteroid course study . 21 . Use contact lens within 30 day Visit 1 . Concomitant use contact lenses also exclude duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>OAG</keyword>
	<keyword>OH</keyword>
</DOC>